Whether you’re newly diagnosed or have been living with ITP for years, managing this blood-clotting disorder means having to carefully assess even ordinary activities for risk of bleeding.

Sanofi (NASDAQ:SNY) announced Tuesday that rilzabrutinib, an oral therapy for an autoimmune blood disorder called immune thrombocytopenia (ITP), reached the primary endpoint in a Phase 3 trial.

The long-held view that ITP is predominantly caused ... patients with co-existent vascular disease. In contrast, worsening thrombocytopenia and severe bleeding has been described in some ...

Patients across the UK with chronic immune thrombocytopenia (ITP) now have another treatment ... Grifols' Tavlesse for adults with the rare blood disorder. Tavlesse (fostamatinib) can now be ...

Doptelet (avatrombopag) – an oral thrombopoietin receptor agonist – has been cleared to boost depleted levels of platelets in the blood of patients with ITP, an autoimmune clotting disorder ...

Plasma medicine helped her to have a family after she developed a blood disorder. Danielle had immune thrombocytopenic purpura (ITP) – her immune system destroyed her platelets, the cell ...